How genomics and AI could help treat cancer more effectively
(NewsNation) — A landmark study from the University of Southern California could hold the key to improving the efficacy of cancer treatment.
Published in Nature Communications, the study revealed how specific gene mutations could help doctors better individually treat cancer patients.
AI model measures how quickly the brain ages
Researchers found more than 700 genetic alters that directly impacted survival rates. They then created an AI tool to predict the responses of lung cancer patients to immunotherapy.
'These discoveries highlight how genetic profiling can play a crucial role in personalizing cancer care,' Ruishan Liu said in a news release.
'By understanding how different mutations influence treatment response, doctors can select the most effective therapies—potentially avoiding ineffective therapies and focusing on those most likely to help.'
30% of parents say their kids use AI for learning, study shows
According to the CDC, around 10% of ovarian cancer and 3% of breast cancer cases are caused by BRCA gene mutation.
'Our goal was to find patterns that might not be obvious at first glance, and then translate these insights into real-world tools that can expand access to immunotherapy for people with cancer,' Lui added.
'One key innovation lies in integrating huge amounts of data with advanced statistical and machine learning techniques to uncover previously unrecognized mutation-treatment interactions.
'This research shows the power of computational science in transforming complex clinical and genomic data into actionable insights. It's deeply fulfilling to contribute to tools and knowledge that can directly improve patient care.'
Copyright 2025 Nexstar Media, Inc. All rights reserved. This material may not be published, broadcast, rewritten, or redistributed.
Hashtags
Try Our AI Features
Explore what Daily8 AI can do for you:
Comments
No comments yet...
Related Articles
Business Insider
a day ago
- Business Insider
I got breast cancer at 30. My treatment means I'll need to delay having kids for 5 to 10 years.
Shortly after my 30th birthday, I was diagnosed with hormone-positive breast cancer. I froze my eggs ahead of my partial mastectomy; treatment means I can't get pregnant for five years. I resent that I have to wait to build a family, but grateful for the chance at survival. When I turned 30, it felt like I was stepping into a new chapter. My partner and I had spent most of our 20s together and were finally in a place where planning for the future felt tangible. After a few difficult years, including the sudden loss of my father and several career missteps, I found myself longing for something joyful and grounding. I wanted purpose, direction, and maybe even a little stability. For the first time, I began picturing myself as a mom. Then I was diagnosed with breast cancer. I was shocked when I got my diagnosis I was diagnosed by accident. I had gone years without seeing a gynecologist. During a routine check-up, I casually mentioned this to my primary care physician, who offered to do a quick breast exam"just in case." That's when she felt a lump. I mentioned that I'd recently been laid off and was in between jobs, without insurance. She told me to reach out once I had coverage and she'd write a prescription for a mammogram. On the drive home, I felt a quiet but urgent instinct not to wait. As soon as I got home, I called her back and asked for the prescription. After a mammogram, ultrasound, and biopsy, I received my diagnosis: stage 1 estrogen receptor-positive, progesterone receptor-positive invasive ductal carcinoma. I couldn't make sense of what I was hearing. Nothing about me fit the narrative I'd grown up believing about who gets breast cancer. I have no family history, don't carry the BRCA gene mutation or any other genetic markers linked to increased risk. What was once seen as a medical anomaly is becoming increasingly common among women my age. My treatment plan included a partial mastectomy, four weeks of daily radiation treatments, and a daily hormone therapy regimen of Tamoxifen, prescribed for five to 10 years, depending on how my system responds. Tamoxifen, often prescribed to treat hormone-positive breast cancer, suppresses estrogen and simulates menopause. It comes with a parade of side effects, including hot flashes, weight gain, and unpredictable mood swings. I learned I can't get pregnant during my treatment Then came a very different kind of blow. Pregnancy while on the medication is strongly discouraged due to the risk of serious complications, including birth defects, miscarriage, and stillbirth. Beyond that, the hormonal surge associated with pregnancy before completing treatment could increase the likelihood of a cancer recurrence. I was scheduled for surgery just one month after my diagnosis. And two weeks before the procedure, my oncologist urged me to freeze my eggs. She explained that pregnancy wouldn't be advised until I was at least 35 due to the complications that could be caused by Tamoxifen — an age that, however dated or insulting it sounds, qualifies as a "geriatric pregnancy" by medical standards. I dissociated my way through a blur of hormone injections, blood draws, and invasive procedures that I barely had time to process. Thankfully, I was spared the financial burden, an immense relief amid the mental, emotional, and physical toll. In 2018, my home state of Connecticut became the first in the nation to require insurance coverage for fertility preservation in cancer patients. Delaying motherhood isn't my choice Though my treatment plan gives me the best chance at survival, it comes at a cost. I'm losing the ability to choose when I want to have kids, and now, I won't be able to have them before 35 at the earliest — possibly as late as 40. I resent that, like it or not, I'll have to be an "old mom" before I ever had the chance to be a "young" one. So far, my partner has been supportive. But I know he always pictured himself becoming a dad sooner rather than later. And when I see him play with our friends' kids, I feel a pang of guilt I can't always ignore. Now we're stuck in limbo while our friends move forward — throwing baby showers, assembling cribs, and posting first-day-of-school photos. I picture myself at preschool, the silver-haired mom whose knees crack at circle time. And I hate that I care. But I do. Then, there's navigating the dissonance between medical necessity and personal expectation. By my 30s, I expected to have it all figured out — career, family, identity. But my timeline was taken from me, redrawn by scans and blood tests, follow-ups, and daily pills. There's also no villain here, no one to blame. It's just a sterile, clinical equation guiding huge decisions about my future. I don't know what's next, but I'm still grateful I'm grateful to be here. I know many people diagnosed with breast cancer never get to consider family planning at all. But I also want to be honest about the loss, the uncertainty, and the weird in-between space where you're healthy but still healing, coping but still grieving the version of your life that never got to happen. I don't know what comes next. Maybe the family I envisioned is still on the way, just a little later than I thought. This isn't the path I planned, but it's the one I'm on. And for now, that has to be enough.
Yahoo
a day ago
- Yahoo
‘Last meal' of sauropod fossil confirms dinosaur lived on plants
(NewsNation) — Scientists have long suspected that a group of dinosaurs known as sauropods subsisted on a diet of plants, but they had no evidence proving their theory. Now they do. Paleontologists in Australia have discovered a layer of plant matter in the stomach contents of a 36-foot-long juvenile sauropod. According to Smithsonian Magazine, the young Diamantinasaurus matildae was unearthed in 2017 in the Winton Formation, a geologic formation in central-western Queensland. The fossil, nicknamed 'Judy,' was discovered by paleontologist Stephen Poropat of Curtin University and his colleagues. The scientists' subsequent findings about the animal's diet were published Monday in the journal Current Biology. Study reveals when the first warm-blooded dinosaurs roamed Earth 'It's the smoking gun, or the steaming guts, as it were — the actual direct evidence in the belly of the beast,' Poropat told The New York Times. The preserved plants, which survived in Judy's gut for at least 94 million years, consisted of material from conifers, flowering plants and extinct seed ferns, according to Smithsonian. The plants were mostly intact, suggesting that the massive dinosaurs, recognized for their long necks and tails, did not chew their food. Poropat said in a Curtin University news release that the condition of the plant matter indicated that sauropods were 'bulk-feeders,' meaning that they swallowed their food whole, allowing their digestive systems to do the work of breaking the food down. The method, still used by some birds and reptiles today, allows a meal to last up to two weeks. To confirm their long-held theory, Poropat and his colleagues had to show that the plants were not just random debris, Smithsonian reported. The fossil's well-preserved condition, including a layer of fossilized skin, indicated that the plants were inside the dinosaur's stomach when it died. Dinosaurs didn't roar like in the movies. Here's how they sounded A lack of plants anywhere near the excavation site also indicated that the plant matter came from inside the beast. 'Ever since the late 19th century, paleontologists have firmly regarded sauropods as herbivores,' Poropat said in the university release. 'However, the specific plants that they ate, and the height above ground at which they fed, have remained unknown — until now.' The research findings have revealed that the eating habits of sauropods may have contributed to their longevity on Earth. 'Sauropods were remarkable animals that roamed the Earth for more than 130 million years. Understanding their diet is critical to understanding their impact on Earth's ecosystems — particularly on plants and other herbivorous species — throughout that time,' Poropat said. Copyright 2025 Nexstar Media, Inc. All rights reserved. This material may not be published, broadcast, rewritten, or redistributed.
Medscape
2 days ago
- Medscape
Fast Five Quiz: Ovarian Cancer Overview
Ovarian cancer poses a significant threat to women's health, often developing quietly and without early symptoms. It is commonly discovered after progression. This late detection, along with resistance to treatment and frequent relapse, contributes to poor outcomes. Although medical and surgical interventions have evolved, survival rates remain low. These challenges highlight the critical importance of early detection methods, precise diagnostic technologies, and individualized care coordinated across medical specialties. How much do you know about ovarian cancer? Test your knowledge with this quick quiz. High-grade serous carcinoma is by far the most prevalent, representing approximately 70%-80% of epithelial ovarian cancer cases. In contrast, the low-grade form of serous carcinoma is much less common (< 5%). Endometrioid and clear cell subtypes are each responsible for about 10% of cases and have known associations with endometriosis. Mucinous carcinomas are uncommon, comprising a small fraction (around 3%) of epithelial ovarian cancers. Learn more about ovarian cancer. According to the National Institute for Health and Care Excellence guidelines, for patients with inherited mutations linked to a higher chance of developing ovarian cancer (eg, alterations in BRCA1, BRCA2, RAD51C, RAD51D, BRIP1, PALB2 ), the most effective preventive surgical procedure is the bilateral salpingo-oophorectomy (which is the removal of both fallopian tubes and ovaries). This intervention has been proven to greatly reduce ovarian cancer risk and enhance long-term survival among these high-risk groups. However, when performed in premenopausal women, it induces menopause. Removing one ovary (unilateral oophorectomy) or the uterus (total hysterectomy) does not offer adequate protection against ovarian cancer. Procedures like cervical conization are unrelated to ovarian cancer and are used to manage cervical abnormalities. Learn more about salpingo-oophorectomy. HRT is typically recommended for women who undergo bilateral salpingo-oophorectomy before reaching the natural age of menopause and have not had breast cancer. This type of surgery causes a sudden and early drop in estrogen levels, which can result in bothersome symptoms and increase the risk for long-term health issues such as bone loss or cardiovascular problems. HRT helps ease these effects and maintain health until the typical menopausal age. In contrast, women older than age 50 years are often already in or near menopause, and HRT is not routinely needed unless specific symptoms arise. Patients who have a history of breast cancer must be assessed on a case-by-case basis because HRT might not be safe. Women with a uterus should be offered combined HRT, whereas women without a uterus should be offered estrogen-only HRT. Additionally, women who have not had their ovaries removed do not experience the abrupt hormonal shift that warrants preventive HRT. Learn more about HRT. Individuals who carry a BRCA1 mutation face a significantly elevated risk of developing ovarian cancer, often at a younger age than those with other hereditary mutations. If a woman with a BRCA1 mutation decides not to undergo surgery to remove her ovaries and fallopian tubes, monitoring for early signs of cancer should begin after age 35 years. This timing aligns with evidence suggesting that BRCA1 -related ovarian cancers tend to occur earlier than those linked to BRCA2 or other genetic variants. Initiating surveillance at age 30 years is generally premature and not part of standard recommendations. For BRCA2 carriers, screening is usually deferred until after age 40 years, whereas those with alterations in genes like RAD51C, RAD51D, BRIP1 , or PALB2 typically begin surveillance after age 45 years. Individuals with Lynch syndrome-related mutations (eg, MLH1, MSH2, MSH6 ) are also advised to start at age 35 years if surgery is postponed. Learn more about breast cancer risk factors. Although mucinous tumors can arise directly from the ovary, many are actually secondary cancers that have spread from other organs, most notably the gastrointestinal system, including the colon and appendix. Distinguishing between primary and metastatic mucinous tumors is crucial for proper diagnosis and management. High-grade serous cancers more commonly begin in the epithelium of the fallopian tubes rather than the ovaries. On the other hand, low-grade serous carcinomas are thought to originate in the ovary and are typically diagnosed in younger females, with outcomes generally more favorable than their high-grade counterparts. Germ cell tumors and sex cord-stromal tumors are far more frequent in adolescents and young adults, with most cases occurring before age 30 years and not in women older than 45. Learn more about endometrioid carcinoma.
